Regeneron Value Stock - Dividend - Research Selection
Regeneron Pharmaceuticals
ISIN: US75886F1075, WKN: 881535
Market price: 667,56 USD
Regeneron Pharmaceuticals Fundamental data and company key figures of the share
| Annual reports in USD | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Key figures | 12-02-2022 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net operating cash flow | 7.081.300.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Expenditures | -3.395.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Free cash flow | 3.686.299.904 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance sheet | |||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | 18.769.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Liabilities & Shareholders equity | 25.434.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Income statement | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | 8.075.000.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Eps (diluted) | 71,970 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Diluted shares outstanding | 113.900.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net sales/revenue | 16.071.700.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
| Description | Data |
|---|---|
| Symbol | REGN |
| Market Capitalization | 74.605.641.728,00 USD |
| Country | United States |
| Indices | MSCI World Index,NASDAQ 100,NASDAQ Comp.,S&P 500 |
| Sectors | Biotechnology |
| Raw Data Source | US GAAP in Millionen USD |
| Stock Split | |
| Internet | www.regeneron.com |
Description of the company
Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. As of December 31, 2011, the Company had 13 product candidates in clinical development. Its Trap-based, late-stage programs are EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as vascular endothelial growth factor (VEGF) trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment.